Introduction: Coronary artery disease progression after primary coronary artery bypass grafting may, beside classical atherosclerosis risk factors, be depending on genetic predisposition.

Methods: We investigated 192 CABG patients (18% female, age: 60.9 +/- 7.4 years). Clinically cardiac adverse events were defined as need for reoperation (n = 88; 46%), reintervention (n = 58; 30%), or angina (n = 89; 46%). Mean follow-up time measured 10.1 +/- 5.1 years. Gene polymorphisms (ApoE, NOS3, LIPC, CETP, SERPINE-1, Prothrombin) were investigated separately and combined (gene risk profile).

Results: Among classical risk factors, arterial hypertension and hypercholesterinemia significantly influenced CAD progression. Single ApoE, NOS3 and LIPC polymorphisms provided limited information. Patients missing the most common ApoE epsilon 3 allele (5,2%), showed recurrent symptoms (p = 0,077) and had more frequently reintervention (p = 0,001). NOS3 a allele was associated with a significant increase for reintervention (p = 0,041) and recurrent symptoms (p = 0,042). Homozygous LIPC patients had a higher reoperation rate (p = 0.049). A gene risk profile enabled us to discriminate between faster and slower occurrence of cardiac adverse events (p = 0.0012).

Conclusion: Single APOE, LIPC and NOS3 polymorphisms permitted limited prognosis of cardiac adverse events in patients after CABG. Risk profile, in contrast, allowed for risk stratification.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2736166PMC
http://dx.doi.org/10.1186/1749-8090-4-46DOI Listing

Publication Analysis

Top Keywords

cardiac adverse
16
adverse events
16
apoe nos3
12
nos3 lipc
12
risk factors
12
gene polymorphisms
8
polymorphisms apoe
8
coronary artery
8
+/- years
8
gene risk
8

Similar Publications

Background: Prostate cancer treatment involves hormonal therapies that may carry cardiovascular risks, particularly for long-term use. Gonadotropin-releasing hormone (GnRH) antagonists, such as degarelix, may offer advantages over agonists, but comprehensive comparative cardiovascular outcomes are not well established. This study aimed to systematically review and analyze the cardiovascular safety profiles of degarelix compared to those of traditional GnRH agonists, providing critical insights for optimizing treatment strategies.

View Article and Find Full Text PDF

Background: Heart failure with preserved ejection fraction (HFpEF) is a heterogeneous entity including patients with different phenotypes of near normal, normal, and supernormal left ventricular (LV) function.

Objectives: To assess the value of resting LV elastance (also known as force) with transthoracic echocardiography (TTE) to identify HFpEF phenotypes.

Methods: In a prospective, observational, multicenter study, 2380 HFpEF patients were recruited from July 2016 to May 2024.

View Article and Find Full Text PDF

Determinants of cerebrospinal fluid leakage in a large cohort of macroprolactinomas.

Ann Endocrinol (Paris)

January 2025

Assistance Publique Hôpitaux de Paris, Pituitary Unit, Pitié-Salpêtrière Hospital, 75013 Paris, France. Electronic address:

Background: Non-functional adrenal incidentaloma (NFAI) is associated with increased risk of adverse cardiometabolic outcome. Identifying predictors of atherosclerotic cardiovascular disease (ASCVD) may enable more appropriate management strategies in patients with NFAI. We aimed to investigate body composition parameters and ASCVD risk in patients with NFAI.

View Article and Find Full Text PDF

Finerenone and new-onset diabetes in heart failure: a prespecified analysis of the FINEARTS-HF trial.

Lancet Diabetes Endocrinol

January 2025

British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, UK. Electronic address:

Background: Data on the effect of mineralocorticoid receptor antagonist therapy on HbA levels and new-onset diabetes are conflicting. We aimed to examine the effect of oral finerenone, compared with placebo, on incident diabetes in the Finerenone Trial to Investigate Efficacy and Safety Superior to Placebo in Patients with Heart Failure (FINEARTS-HF) trial.

Methods: In this randomised, double-blind, placebo-controlled trial, 6001 participants with heart failure with New York Heart Association functional class II-IV, left ventricular ejection fraction 40% or higher, evidence of structural heart disease, and elevated N-terminal pro-B-type natriuretic peptide levels were randomly assigned to finerenone or placebo, administered orally.

View Article and Find Full Text PDF

Background & Aims: Iodine deficiency is linked to multiple adverse health outcomes, but there is scarce knowledge regarding iodine intake and development of chronic hypertension. We aimed to investigate the prospective association between habitual dietary iodine intake and pharmacologically treated hypertension in mothers up to 10 years after delivery.

Methods: The present study is based on data from an ongoing pregnancy cohort and includes 58,629 women without thyroid dysfunction and hypertension at baseline.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!